Incyte Enters Up to $2B Deal with Star Therapeutics Subsidiary to Expand Drug Pipeline
- 6 minutes ago
- 1 min read
Wilmington, NC, June 8, 2026 (Reuters) -- Incyte has struck a collaboration agreement valued at up to $2 billion with a subsidiary of Star Therapeutics. The deal is structured around upfront funding and milestone-based payments tied to development progress. It is aimed at broadening Incyte’s pipeline with new therapeutic candidates and strengthening its long-term growth strategy.
Read full article here.





















